Abbott

CompanyUnited StatesFounded 1888

Abbott develops 5 assets, the furthest approved (dydrogesterone). Mostly small molecule acting on lipid and ceramide metabolism, AR and PGR; based in the United States, founded in 1888.

5
Assets
Furthest: Approved; 33
Trials: 1
Signal

Pipeline

dydrogesterone
Progestogen receptor agonist used in hormone replacement therapy
Approved, Small molecule, PGR, female infertility (Phase 3), menopause (Phase 3)
fenofibrate
PPAR alpha agonist regulating lipid metabolism
Approved, Small molecule, Lipid and ceramide metabolism, PPARA, dyslipidemia, hypercholesterolemia
testosterone
Oral testosterone replacement therapy acting as an androgen receptor agonist.
Approved, Small molecule, Lipid and ceramide metabolism, AR, hormone deficiency, hypoactive sexual desire disorder

2 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms10
Trials69
Signals3
Integrity notices10
Similar companies6

Papers

Combining Contingency Management With Continuous Glucose Monitoring to Support Type 2 Diabetes Prevention and Care
Journal of diabetes science and technology, 26 Sept 2026
Glycemic variability and insulin resistance: A risk marker in adult males predisposed to diabetes mellitus
Medical journal, Armed Forces India, 23 Sept 2026
Colorectal cancer screening with multitarget-stool DNA testing: real-world adherence and follow-up colonoscopy in a large urban academic health system
Current medical research and opinion, 9 Sept 2026

Updated 9 Oct 2026 · 246 sources